Top Adcock shareholders back CFR deal; Cubist wins FDA nod for new Entereg use; Chinese pharmas report profits slump;

@FiercePharma: Two most popular profiles from our Top 10 generics makers report: Teva and Sandoz | Follow @FiercePharma

@CarlyHFierce: Check out the top 10 DTC pharma advertisers from 2013 H1 in the new report. | Follow @CarlyHFierce

> Four Adcock Ingram investors say they're backing a $1.3 billion buyout offer from the Chilean drugmaker CFR Pharmaceuticals; the South African company's biggest shareholder, however, has said it would prefer a domestic owner. Report

> Cubist Pharmaceuticals ($CBST) won FDA approval for expanded use of Entereg, a drug used to speed healing after bowel surgery. Report

> The Finnish drugmaker Orion posted a 12% drop in operating profits for the quarter, to €67 million (about $92 million), thanks to generic competition for its Parkinson's drug. Report

> China's Guangxi Wuzhou Zhongheng Group posted a 29% increase in 9-month net profits to about $92 million. Report

> China's Jiangzhong Pharmaceuticals said its 9-month net profits had dropped 6.8% to 139.2 million yuan, or about $23 million. Report

> India's Symbiotec Pharmalab got a $48 million influx from the private equity firm Actis, which purchased a "significant" stake in the company. Report

Medical Device News

@FierceMedDev: New special report: Top Med Tech Investments of Q3. Report | Follow @FierceMedDev

@MarkHFierce: For Boston Scientific, the first vaginal mesh implant lawsuits are slated to begin in March. Will the company settle? Item | Follow @MarkHFierce

@MichaelGFierce: Implantable, light-sensitive hydrogel could help treat diabetes. More from FierceDrugDelivery | Follow @MichaelGFierce

> Qiagen inks lung cancer diagnostics deal with Clovis Oncology. Story

> CareFusion's latest malfunction draws FDA's most serious label. Article

> European Parliament advances regs that would strengthen scrutiny of high-risk devices. News

> With FDA nod, Cardiovascular Systems targets $1.5B market. More

Biotech News

@FierceBiotech: ICYMI yesterday: 20 BigPharma and biotech mobile apps - 2013. Report | Follow @FierceBiotech

@JohnCFierce: Good thing we have archives--Pain surges after Pfizer commits to 3rd try for long-delayed pain drug Remoxy. Story | Follow @JohnCFierce

@DamianFierce: It's another Class I recall for CareFusion, and these things are starting to catch up with revenue, it seems. News | Follow @DamianFierce

> Novartis grabs an option to buy biotech startup for up to $300M. Story

> Gene therapy upstart launches with $50M and long-term commercial goals. More

> FDA gives J&J a thumbs-up--with a catch--on hep C drug simeprevir. Article

Biotech Research News

@EmilyMFierce:  | Follow @EmilyMFierce

> Harvard, AstraZeneca partner to replace animal testing with 'organs-on-chips.' More

> Takeda, Hopkins developing new pancreatic cancer drugs. Story

> Novartis CDK 4/6 cancer drug effective in preclinical tests, advances to PhI. Item

> New approach could lead to universal flu vaccine. Article

> Mini pancreas grown in lab using mouse cells. Story

Pharma Manufacturing News

@EricPFierce: Is there a connection between pharma DTC spending and job cuts? In some cases, yes. FiercePharma special report | Follow @EricPFierce

> U.K. takes enforcement action against third Wockhardt plant. More

> Authorities seize large load of fake Xanax headed for Egypt. Story

> Teva API plant workers strike over wage gaps. Article

> German contract manufacturers invest €70 million on expansions. Item

> Teva opens $100M Croatia plant as it cuts elsewhere. Report

> Biocad taking biosimilar production to Brazil. More

And Finally... Want big hair? Researchers have found a new way to grow it, at least in mice. Report (sub. req.)